Shanghai Fosun Pharmaceutical Group Co Ltd Announces Details for Sale of Assets to SELLAS Clinicals Holding AG by Sub-subsidiary


Wednesday, 23 Oct 2013 08:00pm EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd announced that its Chongqing-based pharmaceutical research sub-subsidiary will sell intellectual properties as well as related development, commercialization, sales and license rights on Fotagliptin benzoate and Pan-HER Inhibitors owned by the sub-subsidiary and its subsidiary, for EUR 388 million to SELLAS Clinicals Holding AG.